281191-00-2

Upstream product

• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 281191-05-7 (3S,4R,5E)-4-methyl-6-phenyl-3-[(triisopropylsilanyl)oxy]hex-5-enal 
• 2243-53-0 trans-styrylacetic acid 
• 281190-97-4 (2R,3E,1'S,1''R,2''S)-1''-[(p-tolylsulfonyl)amino]indan-2''-yl 2-[3'-(benzyloxy)-1'-hydroxypropyl]-4-phenylbut-3-enoate 
• 281190-96-3 (3E,1'R,2'S)-1'-[(p-tolylsulfonyl)amino]indan-2-yl 4-phenylbut-3-enoate 
• 281190-99-6 (1S,2R,3E)-({1-[2'-(benzyloxy)ethyl]-2-methyl-4-phenylbut-3-enyl}oxy)triisopropylsilane 
• 281191-04-6 (3S,4R,5E)-4-methyl-6-phenyl-3-[(triisopropylsilanyl)oxy]hex-5-en-1-ol 
• 728944-90-9 (2S,3S)-5-(benzyloxy)-2-[(E)-styryl]pentane-1,3-diol 
• 281190-98-5 (3S,4R,5E)-1-(benzyloxy)-4-methyl-6-phenylhex-5-en-3-ol 

Downstream Products

• 155645-51-5 Cryptophycin 4 
• 162473-78-1 desepoxyarenastatin A 
• 162600-54-6 cryptophycin-24 
• 281191-02-4 (2R,2'E,5'S,6'R,7'E)-tert-butyl 2-[(5'-hydroxy-6'-methyl-8'-phenylocta-2',7'-dienoyl)amino]-3-(4-methoxyphenyl)propionate 
• 281191-01-3 (2R,2'E,5'S,6'R,7'E)-tert-butyl 3-(4-methoxyphenyl)-2-({6'-methyl-8'-phenyl-5'-[(triisopropylsilanyl)oxy]octa-2',7'-dienoyl}amino)propionate 
• 281191-03-5 (2S,2'R,1''S,2''R,1''''R)1''-(3'''-{1''''-[(tert-butoxy)carbonyl]-2''''-p-methoxyphenylethylcarbamoyl}allyl)-2''-methyl-4''-phenylbut-3''-enyl 2-[(3'-{[(tert-butoxy)carbonyl]amino}-2'-methylpropionyl)oxy]-4-methylpentanoate 
• 728944-93-2 (2S,1''S,2''R,1''''R)-1''-[3'''-({1''''-[(tert-butoxy)carbonyl]-2''''-(p-methoxyphenyl)ethyl}carbamoyl)allyl]-2''-methyl-4''-phenylbut-3''-enyl 2-[(3'-{[(tert-butoxy)carbonyl]amino}propionyl)oxy]-4-methylpentanoate 
• 162465-18-1 (S)-2-((R)-3-Amino-2-methyl-propionyloxy)-4-methyl-pentanoic acid (E)-(1S,2R)-1-{(E)-3-[(R)-1-carboxy-2-(4-methoxy-phenyl)-ethylcarbamoyl]-allyl}-2-methyl-4-phenyl-but-3-enyl ester 
• 281190-94-1 (2E,5S,6R,7E)-6-methyl-8-phenyl-5-[(triisopropylsilanyl)oxy]octa-2,7-dienoic acid 

Relevant academic research and scientific papers

Synthesis of bioactive natural products by asymmetric syn-and anti-aldol reactions

The use of several variants of the asymmetric aldol reaction as key steps in the syntheses of bioactive target molecules is described. Georg Thieme Verlag Stuttgart.

Asymmetric syntheses of potent antitumor macrolides cryptophycin B and arenastatin A

Efficient and highly stereoselective syntheses of cryptophycin B and arenastatin A, potent cytotoxic agents, are described. An ester-derived titanium enolate mediated syn-aldol reaction was employed to generate the stereocenters C-5 and C-6. The route is convergent and provides a convenient access to the synthesis of structural variants of cryptophycins as well as members of its family. ( Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004).

A convergent synthesis of (+)-cryptophycin B, a potent antitumor macrolide from Nostoc sp. cyanobacteria.

[structure--see text] An efficient and highly stereoselective synthesis of cryptophycin B (2), a potent cytotoxic agent, is described. The ester-derived titanium-enolate-mediated syn-aldol reaction was employed to generate the stereocenters C(5) and C(6). The route is convergent and provides a convenient access to the synthesis of structural variants of cryptophycin B as well as members of its family.